Equity Profile

SYRE

Spyre Therapeutics, Inc.

Health CareBiotechnology$9.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

$-0.75

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $9 billion, it operates in the health care sector, which is increasingly important as the demand for advanced medical solutions grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q1-2026, Spyre reported an EPS of $-0.74, which was worse than the expected $-0.66, leading to a stock increase of 2.72% the following day. The company did not report any revenue figures.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter with a consensus EPS of $-0.75. Investors will be closely watching for any signs of improvement in financial performance.

Bull Case

If the company can beat EPS expectations and show signs of revenue growth, it could signal a turnaround, boosting investor confidence.

Bear Case

A larger-than-expected loss or continued lack of revenue could lead to a decline in stock price as investor sentiment worsens.

Key Metrics to Watch

EPS

$-0.75

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.75?

A better-than-expected EPS could indicate improved cost management and operational efficiency, which is crucial for investor confidence.

Is there any indication of future revenue generation?

Investors are keen to see signs of revenue, as it would suggest that the company is moving towards commercial viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Spyre to improve its EPS based on recent operational changes that have not yet been fully reflected in analyst models.

Supporting Evidence

The company has a history of surprising on the upside, with a 63% EPS beat rate in recent quarters.

The options market is pricing in a larger move than historical averages, indicating that traders expect significant volatility.

Recent operational improvements may not be fully captured in current analyst estimates.

Key Risk

If Spyre can show any signs of revenue generation, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Spyre can turn around its financial performance after a series of losses.

Bull Confirmed If

An EPS of better than $-0.49 would confirm the bull case and suggest a positive trend.

Bear Confirmed If

An EPS worse than $-1.00 would confirm the bear case and likely lead to a significant stock decline.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await clearer guidance.

Miss

A miss on EPS could lead to a drop in stock price, with history suggesting an average decline of around 2.20%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on potential revenue streams or partnerships.
2Details on cost management strategies and their effectiveness.
3Insights into ongoing clinical trials and their timelines.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on future product launches or pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

$-0.75

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q1-2026, Spyre reported an EPS of $-0.74, which was worse than the expected $-0.66, leading to a stock increase of 2.72% the following day. The company did not report any revenue figures.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter with a consensus EPS of $-0.75. Investors will be closely watching for any signs of improvement in financial performance.

Bull Case

If the company can beat EPS expectations and show signs of revenue growth, it could signal a turnaround, boosting investor confidence.

Bear Case

A larger-than-expected loss or continued lack of revenue could lead to a decline in stock price as investor sentiment worsens.

Key Metrics to Watch

EPS

$-0.75

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.75?

A better-than-expected EPS could indicate improved cost management and operational efficiency, which is crucial for investor confidence.

Is there any indication of future revenue generation?

Investors are keen to see signs of revenue, as it would suggest that the company is moving towards commercial viability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Spyre to improve its EPS based on recent operational changes that have not yet been fully reflected in analyst models.

Supporting Evidence

The company has a history of surprising on the upside, with a 63% EPS beat rate in recent quarters.

The options market is pricing in a larger move than historical averages, indicating that traders expect significant volatility.

Recent operational improvements may not be fully captured in current analyst estimates.

Key Risk

If Spyre can show any signs of revenue generation, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Spyre can turn around its financial performance after a series of losses.

Bull Confirmed If

An EPS of better than $-0.49 would confirm the bull case and suggest a positive trend.

Bear Confirmed If

An EPS worse than $-1.00 would confirm the bear case and likely lead to a significant stock decline.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await clearer guidance.

Miss

A miss on EPS could lead to a drop in stock price, with history suggesting an average decline of around 2.20%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on potential revenue streams or partnerships.
2Details on cost management strategies and their effectiveness.
3Insights into ongoing clinical trials and their timelines.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on future product launches or pipeline developments.